Press Releases

01.26.23
OpGen subsidiary Ares Genetics announces granting of key patent in China
01.18.23
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
01.17.23
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
01.11.23
OpGen Announces Closing of $7.5 Million Public Offering
01.06.23
OpGen Announces Pricing of $7.5 Million Public Offering
01.04.23
OpGen Announced 1-for-20 Reverse Stock Split
12.13.22
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
11.10.22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
10.27.22
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
10.27.22
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update